6 citations
,
March 2023 in “Frontiers in Cellular and Infection Microbiology” Golvatinib shows promise as a treatment for Omicron in elderly patients.
Baricitinib works better than methotrexate for severe alopecia areata.
32 citations
,
January 2012 in “International Journal of Dermatology” Skin side effects from EGFR inhibitor cancer treatment can be managed effectively, often without stopping the medication.
April 2023 in “Journal of Investigative Dermatology” Blocking casein kinase 1 in skin cells can help melanocyte precursors move better, potentially helping with conditions like vitiligo or gray hair.
September 2023 in “Drugs in context” Baricitinib is a promising treatment for alopecia areata.
September 2024 in “Drugs & Therapy Perspectives” Ritlecitinib effectively regrows hair in severe alopecia areata and is well tolerated.
1 citations
,
December 2021 in “JAAD case reports” A woman with severe hair loss saw significant hair regrowth after adding platelet-rich plasma injections to her treatment with tofacitinib.
9 citations
,
September 2024 in “Scientific Reports” Cardamonin may help treat oral cancer by promoting cell death and stopping cancer cell growth.
November 2025 in “Biomedicines” JAK1 inhibitors can help reduce itchiness in atopic dermatitis.
6 citations
,
June 2025 in “Nano Biomedicine and Engineering” Smart nano-PROTACs improve cancer treatment by targeting proteins more precisely and reducing side effects.
September 2022 in “Journal of The American Academy of Dermatology” Baricitinib was effective in regrowing eyebrow and eyelash hair in patients with severe alopecia areata.
November 2024 in “Skin Appendage Disorders” Clinicians should consider individual factors and communicate risks and benefits when prescribing ritlecitinib for adolescent alopecia areata.
63 citations
,
April 2018 in “Journal of the American Academy of Dermatology” Topical JAK inhibitors may help treat some skin conditions but need more research.
November 2025 in “FEBS Open Bio” JAK/STAT1 pathway causes hair loss during chemotherapy by reducing Shh in hair follicles.
28 citations
,
September 2016 in “Future oncology” Adverse events from vismodegib can be managed effectively to ensure optimal treatment.
34 citations
,
February 1992 in “Naunyn-schmiedebergs Archives of Pharmacology” Tedisamil and glibenclamide affect cromakalim and minoxidil sulphate differently in rat aorta.
September 2024 in “Journal of the American Academy of Dermatology” Baricitinib maintains significant hair regrowth in severe alopecia areata over three years.
2 citations
,
May 2016 in “Journal of Clinical Oncology” Topical calcitriol may reduce hair loss from chemotherapy at higher doses.
1 citations
,
January 2023 in “Przegląd Dermatologiczny” A man's severe skin reaction from cancer treatment improved with early diagnosis and proper medication.
November 2023 in “The journal of investigative dermatology/Journal of investigative dermatology” OR-101 shows promise for treating alopecia areata by improving hair growth.
45 citations
,
August 2009 in “American Journal Of Pathology” Noggin promotes skin tumors by activating certain cell signaling pathways.
38 citations
,
September 2017 in “Journal of zoo and wildlife medicine” Oclacitinib maleate successfully treated alopecia in Andean bears.
42 citations
,
July 2017 in “Molecular therapy” A form of vitamin E promotes hair growth by activating a specific skin pathway.
26 citations
,
June 2003 in “PubMed” Alpha-difluoromethylornithine prevents cancer in mice but causes hair loss.
July 2024 in “Journal of Investigative Dermatology” ATR12-351 ointment safely delivers LEKTI protein to the skin, reducing enzyme activity in Netherton syndrome.
4 citations
,
January 2001 in “Archives of Biochemistry and Biophysics” Activated ras can protect kidney cells from a certain substance that causes cell death.
4 citations
,
October 2018 in “Asia-Pacific Journal of Clinical Oncology” CDK4/6 inhibitors have improved treatment outcomes for certain advanced breast cancer patients.
October 2018 in “Annals of oncology” Topical calcitriol (BPM31543) is safe for preventing hair loss from chemotherapy and shows some effectiveness.
More research is needed to understand chemotherapy-induced hair loss and its phases.
November 2022 in “Journal of Investigative Dermatology” NCSTN gene mutation causes abnormal skin cell differentiation and more inflammation, contributing to Hidradenitis Suppurativa.